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We appreciate the comments of Bitto and colleagues, who high-
light the potential impact of statins on hepatic endothelial func-
tion in patients with chronic liver disease. Indeed, multiple recent
reports support these observations. In an in vivo animal model of
cirrhosis, simvastatin was shown to upregulate Kruppel-Like
Factor 2 (KLF2) signaling pathways, resulting in deactivation of
hepatic stellate cells (HSC), reduced circulating levels of von
Willebrand Factor (vWF), and improvement in hepatic ﬁbrosis
[1,2]. Statins also have been shown to reduce expression of tissue
factor and thrombin, while increasing the activity of protein C [3].
It is thought that the antithrombotic and vasoprotective effects of
statins are related to increased nitric oxide (NO) availability and
enhanced ﬁbrinolysis, reduced platelet activity and modulation
of the coagulation cascade [4–6]. In a recent prospective cohort
study of 51 patients who received statin therapy, thrombin gen-
eration was signiﬁcantly reduced among statin users, a ﬁnding
which supports the hypothesis that the antithrombotic effects
of statins may be mediated in part by their ability to directly
modify the coagulation cascade [7].
As Bitto and colleagues suggest, it stands to reason that the
vasoprotective effects of statins may be especially pronounced
in patients with non-alcoholic fatty liver disease (NAFLD) and a
metabolic syndrome. Accumulating evidence shows that patients
with NAFLD suffer from hemostatic dysregulation resulting in a
signiﬁcant procoagulant imbalance, compared to healthy controls
[8]. This includes increased thrombin generation and tissue factor
levels, as well as simultaneously increased factor VIII levels and
reduction in the expression of protein C [7,8]. In addition, the
chronic inﬂammatory state associated with NAFLD is marked by
increased circulating free fatty acids, and subsequently increased
levels of E-selectin, myeloperoxidase, and total plasminogen
activator inhibitor-1 (PAI-1), which in turn serve to perpetuate
vascular dysfunction and enhance the procoagulant state [9].
Although a signiﬁcant proportion of patients within the
cohort that we examined from the HALT-C trial demonstrated
baseline steatosis and dyslipidemia, we did not have speciﬁc
markers of endothelial dysfunction or coagulation assays avail-
able for analysis. As such, we look forward with great interest
to future prospective studies designed to address this question.
Currently, the precise mechanisms by which statins may exert
vasoprotective, anti-inﬂammatory and anti-ﬁbrotic effects have
yet to be fully characterized. Large prospective studies with his-
tological endpoints, using well-deﬁned markers of endothelial
dysfunction, are needed in order to deﬁne how and to what
degree statins exert vasoprotective, anti-inﬂammatory and
antithrombotic effects, for the modulation of hepatic ﬁbrosis.Journal of Hepatology 2015 vol. 63 j 276–288 279
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